QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.102.047183v1 305/3/887    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Esbenshade, T. A. Articles by Hancock, A. A. Search for Related Content PubMed PubMed Citation Articles by Esbenshade, T. A. Articles by Hancock, A. A.

NEUROPHARMACOLOGY

Two Novel and Selective Nonimidazole Histamine H₃ Receptor Antagonists A-304121 and A-317920: I. In Vitro Pharmacological Effects

Neuroscience Research, Global Pharmaceutical Research Division, Abbott Laboratories, Abbott Park, Illinois (T.A.E., K.M.K., T.R.M., C.H.K., D.G.W., B.B.Y., G.B.F., R.F., A.A.H.); Pharmacia Corp., St. Louis, Missouri (L.I.D.); Athersys, Cleveland, Ohio (Y.L.B.); and Northwestern University Medical School, Lake Forest, Illinois (M.W.)

Histamine H₃ receptor (H₃R) antagonists enhance neurotransmitter release and are being developed for the treatment of a variety of neurological and cognitive disorders. Many potent histamine H₃R antagonists contain an imidazole moiety that limits receptor selectivity and the tolerability of this class of compounds. Here we present the in vitro pharmacological data for two novel piperazine amide ligands, A-304121 [4-(3-((2R)-2-aminopropanoyl-1-piperazinyl)propoxy)phenyl)cyclopropylmethanone] and A-317920 [N-((1R)-2-(4-(3-(4-(cyclopropylcarbonyl)phenoxy)propyl)-1-piperazinyl)-1-methyl-2-oxo-ethyl-)-2-furamide], and compare them with the imidazole H₃R antagonists ciproxifan, clobenpropit, and thioperamide. Both A-304121 and A-317920 bind potently to recombinant full-length rat H₃R(pK_i values = 8.6 and 9.2, respectively) but have lower potencies for binding the full-length human H₃R (pK_i values = 6.1 and 7.0, respectively). A-304121 and A-317920 are potent antagonists at rat H₃R in reversing R--methylhistamine [(R)--MeHA] inhibition of forskolin-stimulated cAMP formation (pK_b values = 8.0 and 9.1) but weak antagonists at human H₃Rs in cyclase (pK_b values = 6.0 and 6.3) and calcium mobilization (pK_b values = 6.0 and 7.3) assays in cells co-expressing G_qi5-protein. Both compounds potently antagonize native H₃Rs by blocking histamine inhibition of potassium-evoked [³H]histamine release from rat brain cortical synaptosomes (pK_b values = 8.6 and 9.3) and (R)--MeHA reversal of electric field-stimulated guinea pig ileum contractions (pA₂ values = 7.1 and 8.3). A-304121 and A-317920 are also more efficacious inverse agonists in reversing basal guanosine 5'-O-(3-[³⁵S]thio)triphosphate ([³⁵S]GTPS) binding at the human H₃R (pEC₅₀ values = 5.7 and 7.0) than are the imidazole antagonists. These novel and selective piperazine amides represent useful leads for the development of H₃R antagonist therapeutic agents.

Address correspondence to: Dr. Timothy A. Esbenshade, Neuroscience Research, Abbott Laboratories, R4MN, AP9A, 100 Abbott Park Road, Abbott Park, IL 60064. E-mail: Tim.Esbenshade{at}Abbott.com

This article has been cited by other articles:

				A. D. Medhurst, A. R. Atkins, I. J. Beresford, K. Brackenborough, M. A. Briggs, A. R. Calver, J. Cilia, J. E. Cluderay, B. Crook, J. B. Davis, et al. GSK189254, a Novel H3 Receptor Antagonist That Binds to Histamine H3 Receptors in Alzheimer's Disease Brain and Improves Cognitive Performance in Preclinical Models J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 1032 - 1045. [Abstract] [Full Text] [PDF]

				T. A. Esbenshade, G. B. Fox, and M. D. Cowart Histamine h3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders. Mol. Interv., April 1, 2006; 6(2): 77 - 88. [Abstract] [Full Text] [PDF]

				K. M. Krueger, D. G. Witte, L. Ireland-Denny, T. R. Miller, J. L. Baranowski, S. Buckner, I. Milicic, T. A. Esbenshade, and A. A. Hancock G Protein-Dependent Pharmacology of Histamine H3 Receptor Ligands: Evidence for Heterogeneous Active State Receptor Conformations J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 271 - 281. [Abstract] [Full Text] [PDF]

				T. A. Esbenshade, G. B. Fox, K. M. Krueger, T. R. Miller, C. H. Kang, L. I. Denny, D. G. Witte, B. B. Yao, L. Pan, J. Wetter, et al. Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and Selective Histamine H3 Receptor Antagonist with Drug-Like Properties J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 165 - 175. [Abstract] [Full Text] [PDF]

				P. Blandina, M. Efoudebe, G. Cenni, P. Mannaioni, and M. B. Passani Acetylcholine, Histamine, and Cognition: Two Sides of the Same Coin Learn. Mem., January 1, 2004; 11(1): 1 - 8. [Full Text] [PDF]

				G. B. Fox, J. B. Pan, R. J. Radek, A. M. Lewis, R. S. Bitner, T. A. Esbenshade, R. Faghih, Y. L. Bennani, M. Williams, B. B. Yao, et al. Two Novel and Selective Nonimidazole H3 Receptor Antagonists A-304121 and A-317920: II. In Vivo Behavioral and Neurophysiological Characterization J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 897 - 908. [Abstract] [Full Text] [PDF]